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ABSTRACT 
Parasitic nematode infections persist as a serious global public health threat to humans 
and animals. These infections cause debilitating conditions in humans and significant economic 
losses through infection of livestock and crop damage. One of the many parasitic nematode 
infections is lymphatic filariasis; one of the causative agents is Brugia malayi. Presently, the 
treatment of parasitic infection relies on anthelmintics as there are no vaccines. Therefore, 
regular use of the same drugs is expected to produce either loss of potency or resistance. 
Resistance to anthelmintics compromises the control of nematode infections and is also a major 
problem in veterinary and human medicine, resulting in untold morbidity and even mortality. 
Therefore, deciphering pharmacological targets in parasitic nematode species is an urgent need 
to identify potential molecular mechanisms associated with resistance and drug discovery. 
nAChRs (nicotinic acetylcholine receptors) will continue to present targets for such strategies. 
nAChRs are homo- or hetero-pentameric ligand-gated ion channels mediating excitatory 
neurotransmission and muscle activation. In Brugia, there are multiple subtypes of nicotinic 
receptors on the body muscle (M-, P-, L, and N-) that are sensitive to different cholinergic 
anthelmintics. Levamisole is an anthelmintic drug that acts by activating an L-type of nAChR at 
the nematode neuromuscular junction to cause paralysis.  
We hypothesized that the populations of receptor subtypes are dynamic and change to 
compensate and limit the effects of anthelmintic exposure. Therefore, we investigated the issues 
of anthelmintic resistance in vitro using Worminator, which quantitatively measures the motility 
of B. malayi and qRT-PCR (quantitative real time polymerase chain reaction) to analysis the 
relative expression changes of nAChR subunit mRNAs. These were performed to characterize 
xii 
the phenotypic and molecular analysis of nAChR gene expression at different concentrations and 
time intervals. 
We measured the in vitro effects of levamisole on the motility of adult male and female 
Brugia malayi at different time points. We also determined real time IC50 values of different 
concentrations of levamisole at 10 minutes against adult B. malayi which was 10 nM. Both, high 
and low drug concentrations induced an immediate spastic paralysis that lasted for up to 
one hour in worms. However, female worms completely recovered around 4 hours later, whereas 
male worms were only partially desensitized. This suggests a difference in sensitivity to 
levamisole between male and female worms. The variation in motility during levamisole 
incubation was possibly due to differences in nAChR genes expression. Completely recovered 
female worms had upregulation of the Bma-unc-38 gene (ANOVA, P < 0.01). Partially 
desensitized male worms also showed significant upregulation of Bma-unc-38 (ANOVA, P < 
0.01). This indicates that the Bma-unc-38 gene upregulation plays a key role for motility in male 
and female worms. However, the motility variation may be possibly due to differences in 
nAChR genes expression of other nAChR genes also. Female worms under flaccid paralysis had 
increased Bma-unc-29 (ANOVA, P < 0.01).  
Therefore, we concluded that both Bma-unc-38 and Bma-unc-29 genes are important for 
the pharmacology of L-type receptors and motility. Together expression of these genes may 
induce a functional receptor which responded to levamisole. In male worms, robust increased 
expression of Bma-unc-38 and Bma-unc-29 together might delay desensitization. However, in 
female worms, robust expression of Bma-acr-8 and Bma-unc-38 may result in failure to form a 
functional receptor to respond to levamisole. 
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CHAPTER 1.    GENERAL INTRODUCTION  
1.1 Introduction  
Parasitic nematodes are a major problem in both animals and humans, particularly in 
tropical and subtropical regions of the world. Parasitic nematodes also cause economic losses 
through infection and resulting morbidity and even mortality in human and animals. In humans 
and animals, treatment and control of parasitic nematodes relies mainly on the use of available 
anthelmintic drugs, most of which act on ion channels.  
Anthelmintic drugs can be categorized in to three groups based on chemical structure 
and mode of action. The three major classes are the benzimidazoles (BZs), 
imidazothiazoles/tetrahydro pyrimidines and macrocyclic lactones (MLs). The benzimidazoles 
(e.g thiabendazole, mebendazole, albendazole, flubendazole) target beta-tubulin, an important 
protein in maintaining parasite cell structure [1-3]. Imidazothiazoles/tetrahydro pyrimidines (e.g 
levamisole, pyrantel, oxantel, morantel) act on nicotinic acetylcholine receptors (nAChRs), 
which are ligand gated ion channels that mediate fast signal transmission at parasite 
neuromuscular and nerve-nerve junctions [4]. Macrocyclic lactones (e.g ivermectin, abamectin, 
moxidectin) act on glutamate-gated chloride channels (GluCls). Activation of GluCls via ML 
inhibits movement and pharyngeal pumping [5, 6]. New classes of synthetic anthelmintic drugs 
are amino-acetonitrile derivatives (AADs) (e.g monepantel), spiroindoles (e.g derquantel) and 
cyclooctadepsipeptides (e.g emodepside). They have a broad activity against parasites resistant 
to the benzimidazoles, imidazothiazoles and macrocyclic lactones [7-9]. Monepantel acts on 
DEG-3- type nAChRs: ACR-20, ACR-23 and MPTL-1[8]. Derquantel is a first semisynthetic 
anthelmintic that acts as an antagonist of several nAChR types and leads to flaccid paralysis and 
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expulsion from the host [10]. Emodepside is a semisynthetic derivative of PF1022A, which acts 
on SLO-1 Ca-activated K channels and latrophilin (LAT) receptors [11]. 
The recently introduced anthelmintic drug, tribendimidine, targets nAChRs and is approved 
for human use in China [12]. The actions of anthelmintic drugs are by interfering with 
locomotion, feeding, and growth. Unfortunately, resistance has been reported for all 
anthelmintic drug classes, therefore, to slow or overcome resistance it is urgent to decipher the 
pharmacological targets in parasitic nematode species [13, 14].  
This MS study seeks to address two main strategies by which anthelmintic resistance can be 
circumvented. The first aim was to characterize the phenotypic changes with time after worms 
were exposed to different concentrations of levamisole. The second aim was to investigate the 
molecular analysis of nAChRs genes during levamisole exposure to measure the dynamic 
expression changes of the receptor subunits. 
1.2 Thesis Organization 
In this thesis, a general introduction is provided about B. malayi, levamisole and the target 
sites of levamisole used to treat nematode infections. Ion channels are highlighted as targets for 
the majority of available classic anthelmintic drugs and an emphasis is placed on anthelmintic 
drug resistance and the need to overcome drug resistance. Two strategies are proposed as ways 
of understanding drug resistance and these are: the characterization of phenotype change with 
time courses during worms incubated with levamisole and then proceeding to analysis of the 
nAChRs subunits to decipher the relative expression of each subtype. In chapter 2, I have 
reviewed the literature on Brugia malayi, Levamisole, and nicotinic acetylcholine receptors 
(nAChRs) of parasitic nematodes. In chapter 3, I did all the work outlined in this paper. All the 
work in all chapters were done by me. The last chapter is a conclusion of my MSc research and 
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CHAPTER 2.    LITERATURE REVIEW  
2.1 Parasitic Nematodes 
 Parasites are organisms that live in or outside another organism known as the host, and 
benefit at the expense of the host. Parasites broadly include viruses and bacteria along with 
protozoa, helminths and arthropods. Parasites are a major cause of disease in the host and may 
possibly cause death, poor growth, weight loss, compromised immune system, anemia and in 
humans, impaired cognitive skills. Parasites are categorized in to endoparasites and 
ectoparasites. Endoparasites live inside the body and the ectoparasites lives outside the body. In 
animals, endoparasites may live in the blood, muscles, liver, brain or digestive tract [15]. 
 Nematodes are nonsegmented roundworms belong to the phylum Nematoda. More than 
50% of the 25,000 nematode species are parasitic [16]. These include the soil-transmitted 
helminths (STHs) and filarial worms. Parasitic nematodes infection causes global health and 
economic impacts. According to the World Health Organization (WHO), four of the seventeen 
“Neglected Tropical Diseases” (NTDs) are caused by soil-transmitted helminths (STHs) and 
filarial worms. Neglected tropical diseases (NTDs) are a group of infectious diseases 
categorized by the neglect they have been suffered in terms of funding, research, and policy. 
The seventeen NTDs are Lymphatic filariasis, Soil-transmitted helminthiases, Dracunculiasis 
(guinea-worm disease), Buruli ulcer, Chagas disease, Dengue and Chikungunya, 
Echinococcosis, Foodborne trematodiases, Human African trypanosomiasis (sleeping sickness), 
Leishmaniasis, Leprosy (Hansen’s disease), Onchocerciasis (river blindness), Rabies, 
Schistosomiasis, Taeniasis/Cysticercosis, Trachoma and Yaws (Endemic treponematoses) [17]. 
One of the NTDs is Filariases (lymphatic filariasis and onchocerciasis) which is caused 
by filarial worms. Lymphatic filariasis is among the five diseases primarily the goals and vision 
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(leprosy, sleeping sickness, blinding trachoma, guinea worm disease, and lymphatic filariasis), 
to be eliminated by NTD program at WHO [18]. 
 Parasitic nematode infections affect approximately one billion people primarily living 
in developing areas of sub-Saharan Africa, Asia and the Americas with poor sanitation and lack 
of health education program [19].  Parasitic nematode infections cause debilitating conditions 
and serious problems in health of human and livestock. Moreover, they jeopardize food security 
and cause significant economic loss [18, 20, 21].  Consequently, the infection through the 
communities are persistently trapped in a cycle of poverty and disease (Figure 2-1). 
 
Figure 2-1 Global distribution of neglected tropical diseases. 
https://www.cdc.gov/globalhealth/ntd/diseases/ntd-worldmap-static.html 
2.2 Lymphatic filariasis (Elephantiasis) 
Lymphatic filariasis (LF), commonly known as elephantiasis, is a NTD infection, caused 
by thread-like vector born nematodes of the family filariodidea. These include Wuchereria 
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bancrofti, Brugia malayi and Brugia timori. Almost 90% of LF cases are caused by W. 
bancrofti, while B. malayi and B. timori account for the remaining 10% of infections [22]. 
The mode of transmission of the parasites that cause LF is via blood sucking vector 
mosquitoes. Different types of mosquito transmit  LF including, Culex, Anopheles, Mansonia 
and Aedes [23].  LF is a major hinderance to socioeconomic development and causes immense 
psychosocial suffering among the affected. According to the WHO, LF is the second leading 
cause of chronic disability globally after mental illness. LF damages the lymphatic system 
resulting in peripheral swelling, causing pain and severe disability [23, 24].  Lymphatic 
filariasis affects ∼120 million people worldwide, most of whom reside in developing countries, 
with over one billion being at risk of acquiring this infection in 83 countries and about 40 
million deformed and debilitated as a result of the disease [23], [25, 26]. The majority of LF 
cases occur in Africa (Figure 2-2). 
 




The majority of LF infections are asymptomatic because they do not manifest strong 
inflammatory responses even though microfilaria circulate in the system, but symptoms can 
develop years after infection. When LF develops in to chronic conditions, acute symptoms 
include inflammation of  the skin, lymphdoma or elephantiasis and hydrocele (scrotal swelling) 
[27, 28]. Elephantiasis impairs the lymphatic system and develops to abnormal enlargement of 
peripheral body parts. It is the most chronic and obvious symptom, occurring in a small 
percentage of persons of LF cases. Body deformities often lead to social stigma, sub-optimal 
mental health and loss of income earnings opportunities and increase medical expenses and 
their caretakers [29-31]. 
The life cycle of parasites that cause LF involve both mosquito and human stages 
(Figure 2-4). Adult worms live in the lumen of the lymphatic system and have been found in 
parts of the lymphatic circulation. The majority of worms live in the lower and upper part of the 
lymphatic system including the male genitalia. After mating, the female worm releases around 
10,000 or more offspring per day. The worms release L1 larvae (microfilariae) instead of eggs. 
Each microfilaria measures approximately 270 μm by 10 μm and contains nuclei that 
characteristically do not extend to the tip of the tail. One distinguishing feature of microfilaria is 
they are encased in a sheath comprised of chitin, a remnant of its eggshell. Microfilariae migrate 
from the lymphatic system to the blood circulation. Most of them aggregate in the peripheral 
blood at night (between 10 pm and 6 am) termed nocturnal periodicity. However, during the 
daytime, the microfilariae migrate to the lung capillaries as activity of host is increased. During 
sleep the microfilaria migrate to peripheral blood circulation due to a pH change in the 
pulmonary venous circulation [32]. Microfilariae live for about 1.5 years and must be ingested 
by a mosquito to continue their life cycle.  
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During a blood meal, infected mosquitoes introduce L3 larvae into the body of a human 
host where they penetrate the bite wound and migrate to the lymphatic vessels and develop into 
adult worms. Adult B. malayi females are larger (measuring 43 – 55 mm in length by 130 – 170 
µm in width) than adult males (measuring 13 – 23 mm in length by 70 – 80 µm in width). Adult 
worms produce sheathed microfilariae (measuring 177 – 230 µm in length by 5 – 7 µm in 
width) which typically enter the bloodstream reaching the peripheral blood and are ready to be 
ingested by the mosquito during another blood meal. Microfilariae shed their sheaths and 
migrate to mosquito’s thoracic muscles via midgut where they moult into L1 larvae and 
subsequently develop into L3. The L3 larvae then migrate to the mosquito’s head and proboscis, 
whereby they can infect another human, thus continuing the transmission cycle.  
 
Figure 2-3 Adult female Brugia malayi in well plate. 
Lymphatic filariasis should be suspected in an individual who lives in an endemic area. 
A definitive diagnosis has traditionally depended upon microscopically observing the 
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characteristic microfilariae in the blood. Blood samples for microfilariae detection are usually 
collected at night because lymphatic filariasis due to nocturnal periodicity. An antigen test is an 
alternative method that has been developed to detect circulating antigens which is more 
sensitive than microscopy [33-37]. These tests are available in different form such as ELISA 
(Enzyme-linked immunosorbent assay) test or an immunochromatographic card, adult worm 
antigen and are very sensitive and specific. The ELISA has a sensitivity approaching 100 
percent in microfilaremic patients. For both assays, the circulating filarial antigen remains 
diurnally constant, so blood for diagnosis can be collected during the day. PCR-based tests have 
been developed, but while used to monitor filarial infection in mosquitos, are currently not 
routinely used in clinical practice [38-40]. A rapid serological test has been developed which 
detect the human antibody IgG against the worms, these tests are used in clinical diagnosis of 
LF [41, 42]. Moreover, a noninvasive method of diagnosis has been also developed which is 
used to monitor the efficacy of antifilarial drugs such as DEC. Ultrasound examination provides 
a picture of filaria in lymphatic vessels known as the “filarial dance sign” which is reflective of 
nests of live worms in the lymphatics [43]. Treatment strategies for LF rely on chemotherapy 
through mass drug administration (MDA). It is recommended all patients be treated, because 
some patients are asymptomatic. However, early treatment prevents subsequent lymphatic 
damage and may reverse lymphatic dysfunction [44]. The treatment of choice for mono-infected 
patients, is diethylcarbamazine (DEC) has both macrofilaricidal (adult worm) and 
microfilaricidal properties. The treatment is given as a single a dose of 6 mg/kg/day for 12 
consecutive days for a total dose of 72 mg/kg. DEC decreases largely microfilaremia within one 
month and in some patients reverses existing damages. The addition of doxycycline to DEC 
improves the effect of microfilaricidal activity and decreases LF pathology [43, 45-47]. 
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However, DEC is only partially effective against the adult worms, thus, repeat treatment is 
needed every 6-12 months [44]. Alternative drugs, ivermectin (150–200 µg/kg) and albendazole 
(200 mg), have been used in MDA to reduce transmission and microfilarial blood levels [48, 
49].  However, these drugs kill only the microfilaria, with partial activity against adult worms 
which can live for an average of 5–10 years and will continue to produce microfilariae. 
Currently, effective novel drugs are critically needed. DEC should not be given to patients who 
may also have onchocerciasis as it can worsen onchocercal eye disease (Mazzotti reaction) [50]. 
Moreover, prior treatment density of Loa loa microfilarial should be ruled out [51]. Co-
infection of LF with onchocerciasis can be treated with combination of ivermectin and 
albendazole. Bancroftian filariasis treatment is more effective using triple therapy that include 
DEC, albendazole and ivermectin than DEC and albendazole. However, more studies are 
needed to ascertain the safety of this triple drug therapy, particularly in individuals who are co-
infected with onchocerciasis and loiasis. Aside from the use of anthelmintic drugs, strategies to 
improve chronic sequelae of LF, including lymphedema and elephantiasis. In both conditions, 
increased personal hygiene and antibiotic treatment prevents acute bacterial infections and 






Figure 2-4 Life cycle of Brugia malayi. 
https://www.cdc.gov/parasites/images/lymphaticfilariasis/b_malayi_lifecycle.gif 
2.3 Nicotinic acetylcholine receptors (nAChRs) 
Nicotinic acetylcholine receptors (nAChRs) are ligand ion channel made up of five 
subunits arranged around a central pore that is permeable to cations [52, 53]. The nAChRs are 
large transmembrane proteins and members of the Cys-loop ligand-gated ion channels that 
mediate fast synaptic transmission in the neurons and muscles of vertebrates and invertebrates. 
They are an important site for many anthelmintics and unlike the muscarinic AChRs, the 
nAChR receptors are not coupled to second messenger cascades [52, 54, 55]. Each nAChR 
subunit consists of an N-terminal, extracellular domain that contains the cys-loop (two cysteine 
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residues separated by 13 amino acids), six loops (A–F) and four transmembrane domains (TM1 
– TM4). TM2 forms the lining of the ion pore (Figure 2-5).  
Subunits of nAChR are categorized in to α and non-α, by which α subunits contain two 
adjacent cysteine residues (connected by a strained disulfide bond) in loop C which is an 
important site for acetylcholine binding while subunits without this motif are non-α subunits. 
Pentameric receptor of nAChR contains a minimum two α subunits while the binding site of 
ACh involves an α subunit and an adjacent subunit [56]. nAChRs are made up of the same 
subunits or different subunits. Homopentamers are the same subunits, whereas the nonidentical 
subunits are heteropentamers and contain at least two  subunits [57, 58].  
 
Figure 2-5  Structure of the nicotinic acetylcholine receptor. Each nAChR consists of five 
subunits arranged around a cationic channel pore. (Brown et al., 2006) 
2.3.1 Parasitic nematode nAChRs   
The nAChRs of parasitic nematodes are the site of action of anthelmintic drugs such as 
levamisole, pyrantel, oxantel, bephenium and morantel. Anthelmintic drugs activate the 
receptors found in the parasite body muscle and result in worm contraction [59]. Most studies of 
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parasitic nematode nAChRs were performed in Ascaris suum (clade III). Initial patch clamp  
analysis from Ascaris muscles revealed  the presence of three pharmacologically distinct acetyl 
choline-activated channel types, L-type activated  by levamisole and pyrantel, N-type activated 
by nicotine and oxantel and B-type by bephenium [60] [61, 62]. Single channel recordings 
showed low levamisole concentrations (1 – 10 M) cause channel opening and high levamisole 
concentrations (30 and 90 M) cause flickering channel block. Levamisole activates the  three 
channels but preferentially activates the L- type [61]. Unlike in C. elegans where the actions of 
levamisole and nicotine are selective (levamisole-sensitive currents are not activated by nicotine 
and vice versa), the differences in agonist action are subtler in A. suum. For instance, although 
levamisole preferentially activates L-type channels, it also opens N- and B-type channels to a 
lesser extent. Bephenium preferentially activates B-type channels but also opens some L-type 
but not N-type channels. Hence, nAChR types in A. suum are less distinct in terms of agonist 
pharmacology than those in C. elegans. At high concentrations, levamisole activates all three 
nAChR types in A. suum. 
             In the strongylid nematode Oesophagostomum dentatum (clade V) four levamisole-
sensitive channels have been identified on body wall muscle [63]. In H. contortus, Teladorsagia 
circumcincta and Trichostrongylus colubreformis (all clade V) genes are orthologous to C. 
elegans unc-29, unc-63, unc-38 and lev-1 genes. However, they differ only in one gene which is 
lev-8 of C. elegans. Instead of that a truncated variant (Hco-acr-8b) of a related gene, Hco-acr-




2.4 Anthelmintics and Anthelmintic Resistance  
2.4.1 Anthelmintics  
Drugs used to treat an infection caused by parasites are called anthelmintics [65]. 
Helminths are invertebrate organisms characterized by elongated, flat or round bodies and 
generally visible to naked eye during adult stages. Helminths can be either free-living or 
parasitic in nature. In their adult form, they do not multiply in humans. Generally, helminths are 
classified in to three classes namely: nematodes (roundworms), trematodes (flukes) and 
cestodes (tapeworms) [66]. Anthelmintics selectively kill or eject the parasite from body, 
without causing significant side effects to the host [6]. Helminths are categorized in to two 
phylum which are nematodes (roundworms) and platyhelminths (trematodes and cestodes) [67, 
68]. Even though, the prevalence of parasitic infection is high, anthelmintic drug discovery and 
development by pharmaceutical companies is slow. The most contributing factor that delay 
discovering of the new drugs is most of those infections are prevalent in developing countries 
which lack the resources to support a profitable drug market [69]. Novel drug discovery is 
estimated at US $ 40 million for livestock use, and more than US $ 800 million for human use 
 The global market for antiparasitic drugs and chemicals is estimated at US $12 billion for plant 
pathogens, $11 billion for livestock and companion animals, and $0.5 billion for human health 
[70] [71-73]. Initially most of anthelmintic drugs used to treat humans were developed and 
marketed as veterinary drugs [74] [75, 76]. The few classes of anthelmintics are 
benzimidazoles, imidazothiazoles, tetrahydopyrimidines, macrocyclic lactones, amino-
acetonitrile derivatives, spiroindoles and cyclooctadepsipeptides. 
2.4.2 Imidazothiazoles 
Imidazothiazoles are bicyclic heterocycle consisting of an imidazole ring fused to a 
thiazole ring; it contains three hetero atoms in structure two nitrogen and one sulphur atom, and 
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act as nAChR agonists. Imidazothiazoles bind to the ion channel nAChRs, that cause paralysis 
of the worms and cause their expulsion from the body [4]. The first drug member of the 
Imidazothiazoles is Tetramisole, an aminothiazol derivative constitutes a racemic mixture of 
50% L- or S- and D- or R-isomers [77]. The L-isomer is more potent than the racemic mixture 
or the D-isomer [78, 79]. Consequently, the D-isomer was removed from the racemic mixture 
and this led to the development of the L-isomer as levamisole. The detailed mode of action of 
levamisole, the only existing drug in this class, has been carefully studied at the single-channel 
level in nematode body wall muscles [61, 80, 81] using the patch-clamp technique at the single-
channel level in A. suum muscle. Levamisole (1 – 90 M concentrations) causes activation of 
cation-selective channels, in addition to voltage-sensitive open channel blocking and 
desensitization. Recently, it has been shown that adult Brugia malayi, possesses levamisole-
sensitive nAChRs [63, 82]. 
2.4.3 Anthelmintic resistance 
In broad terms, anthelmintic resistance is referred to as loss of sensitivity of a drug in a 
population of parasites that were once susceptible to the drug. Anthelmintic resistance develops 
when more individuals in a parasite population that were hitherto affected by a given drug 
dose/concentration become unaffected or when there is a decline in the efficiency of a drug 
against a hitherto susceptible parasite population [1, 83]. This definition does not however 
suggest what causes the decline in the efficiency of a drug. An alternative definition of 
anthelmintic resistance that points to an origin states that anthelmintic resistance is “the 
genetically transmitted loss of sensitivity in worm populations that were previously sensitive to 
the same drug” (Köhler, 2001). This definition emphasizes the importance of genetics in 
determining drug resistance. Detecting resistance at the early stage is necessary in preventing an 
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“endemic” problem. Usually, the first sign of resistance is treatment failure. Development of 
resistance in numerous veterinary parasite species has occurred, with concerns that may extend 
to humans. This happens, due to repeated and inappropriate use of anthelmintics [84-86]. 
Moreover, mechanism action of drugs which share the same site are more likely vulnerable to 
resistance to happen to other drugs in the same class (side resistance) [87]. Drugs from one class 
and another class but share similar targets also increased the likelihood for the development of 
cross resistance [83]. Hence, resistance to most of anthelmintic drugs can develop. 
Unfortunately, the onset of anthelmintic resistance can be rapid, thiabendazole resistance 
occurred only three years after its introduction to the market [88]. Reports of resistance to 
anthelmintics in various parts of the world have been well documented [14, 89]. Despite the 
numerous reports of anthelmintic resistance, the mechanisms by which resistance occurs remain 
to be fully elucidated. Resistance mechanisms may include: (i) mutation or deletion of one or 
more amino acids in the target genes, (drug target modification) (ii) reduction in the number of 
receptors, (iii) decreased affinity of receptors for drugs, (iv) absence of bioactivating enzymes, 
(iv) gender variation in drug sensitivity; variation in sensitivity by the same parasite species in 
different hosts; variation in sensitivity by the same parasite species in different hosts; [87] and 
(v) target gene amplification in order to overcome drug action [90-93]. Management practices 
can also delay or overcome anthelmintic resistance [94].  
Anthelmintic resistance can be delayed or overcome by: (i) identifying new drug targets 
with different pharmacological profiles from those of existing drugs, (ii) introducing new 
anthelmintics with different modes of action from those of existing anthelmintics, (iii) 
combination therapy, with members of the combination from different drug classes, (iv) rotating 
drugs with different modes of action between dosing seasons, and (v) keeping some parasites in 
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untreated refugia. Refugium is an area in which a population of organisms can survive through a 
period of unfavorable conditions [94-96]. A detailed understanding of the biochemical and 
genetic basis of anthelmintic action is, therefore, crucial as this will allow for the development of 
sensitive assays for early detection and, hence, more efficient management of anthelmintic 
resistance [97]. 
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3.1 Abstract 
Parasitic nematodes are the causative agents of many infections such as elephantiasis; 
one of the causative agents is B. malayi. Control of parasitic infections rely on the use of 
anthelmintic drugs as there is currently no effective vaccine against the infections. Therefore, 
regular use of the same drugs is expected to produce either loss of potency or resistance. 
Deciphering pharmacological targets in parasitic nematode species is urgently needed to 
identify potential molecular mechanisms associated with resistance. Circumvention of 
resistance will involve the discovery of new anthelmintics, either singly or as combination 
therapies, and nicotinic acetylcholine receptor (nAChRs) will continue to present targets for 
such strategies. Therefore, we have investigated the issue of desensitization of levamisole in 
vitro using B. malayi as a model through motility phenotyping (Worminator) and qRT-PCR 
(quantitative real time polymerase chain reaction). The two techniques were performed to 
characterize the phenotypic and molecular analysis of nAChR subunit expression at different 
time points. In B. malayi, there are multiple subtypes of nicotinic receptors on their body muscle 





Levamisole is an anthelmintic drug that acts by activating L-type nAChRs at the nematode 
neuromuscular junction and causing paralysis. In vitro, we measured the effects of levamisole on 
motility of adult male and female B. malayi at different time courses. High and low drug 
concentrations of levamisole induce a spastic paralysis that lasted for up to one hour. However, 
female worms completely recovered at four hours, whereas male worms did not. This suggests, a 
difference in sensitivity to levamisole between male and female worms. The variation in motility 
after levamisole incubation was possibly due to differences in nAChR subunit gene expression. 
Completely recovered female and partially recovered had increased abundance (ANOVA, P < 
0.01) of mRNA encoding Bma-unc-38, while female worms under flaccid paralysis had increased 
abundance (ANOVA, P < 0.01) of mRNA encoding Bma-unc-29. This potentially indicates that 
Bma-unc-38 upregulation is required for recovery of motility. However, Bma-unc-29 is required 
for rescuing worms from spastic to flaccid paralysis. 
Keywords 
Levamisole; Brugia malayi; ion channel receptor; subtypes; relative expression; resistance, 
nAChR. 
3.2 Significance  
Parasitic nematodes globally have an impact on health and economics. They infect 
animals, including livestock, humans and plants. Their control in human and veterinary 
medicine relies on the available anthelmintic drugs. However, resistance against these drugs 
compromises the sustainable control nematode parasites. Acetylcholine receptors (AChRs) are a 
ligand gated ion channel required for body movement in parasitic nematodes and are targets of 
“classical” anthelmintic drugs such as levamisole and pyrantel. Here we used the Worminator to 
characterize the phenotypic changes and qRT-PCR to measure relative expression changes in 
male and female worms exposed to levamisole. We have found that desensitization in male and 
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female worms is associated with Bma-unc-38 upregulation. However, in worms under flaccid 
paralysis we observed Bma-unc-29 upregulation. These genetic changes may allow for an 
increase of nAChRs that contributes to the recovery of motility and enhance resistance. 
3.3 Introduction 
 Neglected tropical diseases (NTDs) are communicable diseases caused by nematode 
parasites which affect about 2 billion people of the global population. Poverty, inadequate 
sanitation and in close contact with infectious vectors and domestic animals increased 
susceptibility to these infections [98-101]. Lymphatic filariasis is one of the neglected tropical 
diseases caused by Brugia malayi, Wuchereria Bancrofti and Brugia timori. Globally lymphatic 
filariasis is the second leading cause of permanent and long term disabilities [102]. It has infected 
around 120 million people in 73 countries, and an estimated 1.34 billion live in areas where 
lymphatic filariasis is endemic and are at risk of infection. About 40 million people suffer from 
the painful and disabling clinical manifestations of the disease [89, 102-105]. The parasite 
microfilaria is transmitted by vector mosquitos; therefore, integrated vector management 
significantly reduces the spread of infection. Currently, there is no effective vaccine against 
nematodes, therefore treatment strategies mainly rely on a number of classes of anthelmintic 
drugs. Many anthelmintic agents are selective and produce spastic paralysis after causing 
depolarization of the muscle of nematodes [106]. However, development of drug resistance is a 
major concern [107, 108]. Available treatments kill the parasite larvae (microfilariae) and 
paralyze the adult worms. But the mechanism of action is poorly understood. Studies are needs 
to advance the information on the available classical anthelmintic drugs. 
Our study investigates the phenotype change and molecular analysis of desensitization 
can lead to discovery of novel site of action. nAChRs are pentameric ligand gated cation channels, 
which have a pore in the center and are activated by binding of the neurotransmitter and other 
29 
 
cholinergic agonists to their alpha subunits [109]. These ion channels, if they are composed of 
five identical subunits, are described as homomeric or if these are different heteromeric. Adult B. 
malayi, possesses levamisole-sensitive nAChRs which are made up of BMA-UNC-38, BMA-
UNC-29, BMA-UNC-63, and BMA-ACR-8 channels [110-112]. 
Most mode of action studies of anthelmintic drugs have been conducted on the model 
nematode, Caenorhabditis elegans, which is not a parasite, it is free living nematode. It is 
evolutionarily distant from parasitic nematodes and it does not possess “parasitism genes”  [112]. 
This separation highlights the need for anthelmintic studies using real parasites, but until now 
many of the techniques applied on C. elegans have not been tractable in animal parasites. 
Recently, there are many more systems for the measurement of nematode movement in 
vitro, one of them is the worminator system. The Worminator is an image processing computer 
attached to a high definition video camera for studying phenotypic movement [113]. The worm 
assay is a computer application utilizing high definition (HD) video as an input to assess motility 
of macro parasites (i.e. visible to the naked eye) in 12, 24, 48, and 96 well cell culture plates for 
the purpose of screening of potential anthelmintic drug compounds [114]. The program analyzes 
differences in worm position from successive video frames to determine the rate of movement 
using the Lucas–Kanade Optical flow algorithm. The lower the movement, the lower the motility 
number and more effective the drug is against the parasite. 
To characterize and quantify the gene expression changes of treated and control worms, 
qRT-PCR is a good technique, especially useful for confirming expression of targeted genes. 
Detection of amplified product can be done with specific fluorescent probes or with DNA binding 
dye like SYBR green which is rapid and sensitive. qRT-PCR is a powerful tool to measure 
differentially expressed transcripts in B. malayi. 
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Levamisole is a cholinergic anthelmintic drug which acts by interfering with the function 
on nAChRs found at the neuromuscular junctions of nematodes [115, 116]. Evidence point out 
that levamisole resistance may involve a decrease in the number of nAChRs and/or mutational 
change in receptor function [117-120]. Therefore, we hypothesized that populations of receptors 
are dynamic and change to compensate and limit the effects of anthelmintic exposure. We 
investigated our hypothesis using two strategies, first we applied different concentrations of 
levamisole to B. malayi to measure motility at different times and concentrations using 
Worminator, and to quantify motility relative expression changes of nAChRs subunit genes using 
qRT-PCR.  
3.4 Materials and Methods 
To study the phenotype and molecular analysis of desensitization to levamisole in male 
and female adult B. malayi, we used the following materials and methods. Levamisole 
hydrochloride was purchased from MP Biomedicals, LLC. 
3.4.1 Parasites 
Female and male adult B. malayi used in this study were supplied from the NIH/NIAID 
Filariasis Research Reagent Resource Center (FR3) College of Veterinary Medicine, University 
of Georgia, Athens, GA. The worms were maintained in non-phenol red Roswell Park 
Memorial Institute (RPMI: Invitrogen) 1640 medium supplemented with 10% heat-inactivated 
FBS (Fisher Scientific) and 1% penicillin-streptomycin (Invitrogen) at a temperature of 37 °C in 
a 5% CO2 incubator. The worms were sorted individually in 24-well microtiter plates 
containing 1ml of media for the studies of these effects of levamisole on motility. 
3.4.2 nAChR Primer Design  
Complementary DNA primers were designed from sequences obtained from worm base 
with Primer3 plus software. The product size of primers for qRT-PCR range between 150-200bp 
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(Table 3.1). We also required that the nucleotides have a maximum GC content of 40%. All 
primer sets had a calculated annealing temperature of ≥ 58◦C. Primers were ordered from DNA 
facility at Iowa State University, Department of Molecular Biology. Primer concentration for each 
primer were resuspended and diluted to a working concentration. Contamination of primers 
checked using water as control by setting up a PCR with the same primers. 
Table 3.1 Primer sequences used for qRT-PCR experiments BP, base pairs; F, forward; R, 
reverse. Bp size (150-200bp). 
nAChR subunits Forward primer Reverse primer 
Bma-acr-8 F: 5′ CGGTTTCCAAATTGATGTTC -3′ F: 5′ AGGATACAGGCGTTCATGTC -3′ 
Bma-unc-38 F: 5′ GTTGCCATTTCAAGTTTGGT-3′ F: 5′ TCGACGGACGGATAGTAGTC -3′ 
Bma-unc-29 F: 5′ GGCTGCCAGATATCGTTTTA-3′ F: 5′ ACGGGAAGAATTCAACATCA -3′ 
Bma-unc-63 F: 5′ CAGAAACATTGCTTGGCTTT-3′ F: 5′ AGGTGATTCACAGCATGGAT -3′ 
Bma-acr-16 F: 5′ CGACCAGGAGTTCATCTCTC-3′ F:5′GAAATTGGGCTCTTTCCATT -3′ 
Bma-acr-26 F: 5′ GTTCTTCTTGCATTCTCGGT-3′ F:5′TCAAATGGACCACGATGATG -3′ 
Bma-gapdh F:5′GACGGAGCCGGAGTATGTTGT-3′ F:5′CAAACAATTGGTGGTGCAAG -3′ 
 
3.4.3 Worminator assay 
Motility phenotypes were measured using Worminator system to quantify 
simultaneously the movement of the worms in each well of a 24-well plate. To obtain the videos 
of the movements of each worm for mean motility the worm assay version 1.4 software was 
used. Worm movement as mean motility unit (MMU) were measured for 30 sec after incubated 
at different concentrations of levamisole. Our observations revealed that motility in male and 
female worms is different after incubation with same concentrations of levamisole for four 
hours. We prepared different stock solutions of levamisole and serially diluted using deionized 
water to yield working concentrations of 3 ոM, 10 nM, 30 nM, 100 nM, 300 nM, 1 µM, 3 µM, 
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10 µM and 100 µM. One adult B. malayi was added to an individual well of a 24 well cell 
culture plate. Levamisole (1 µl) solutions were added to each of wells in order to further achieve 
a final levamisole concentration. Deionized water (1 µl) was added to the negative control wells 
contained RPMI solution. The prepared plate was then incubated at 37 °C and 5% CO2 for 
several hours to optimize the temperature. Worminator readings were recorded prior to addition 
of the drug and immediately following addition of the drug, and at 10 min, 20 min, 30 min, 
40min, 50 min ,1 h, 2 h and 4 h post-levamisole treatment. 
3.4.4 RNA extraction and reverse transcriptions by PCR  
Worms were crushed under liquid nitrogen with a plastic pestle and re-suspended in 
Trizole reagent (ambion, Carlsbad, CA). Total RNA was prepared according to the 
manufacturer’s instructions with minor modifications. The quantity of RNA was measured with 
Thermo Scientific Nano-drop using Spectrophotometer (Pharmacia Biotech, Piscataway, NJ). 
First-strand complementary DNA was synthesized from total RNA using Invitrogen 
superscriptTM IV VILOTM master mix (Invitrogen by Thermo Fisher scientific, Vilnius, 
Lithuania) according to the manufacturer’s instructions. 
3.4.5 SYBR Green quantitative RT-PCR 
The PCR reactions were carried out in 96 well microtiter plate wells in a 20 µl reaction 
volume with PowerUpTM SYBRTM Green Master Mix (applied biosystems, Vilnius, Lithuania) 
and SsoadvancedTM Universal SYBR Green supermix with optimized concentrations of specific 
primers. Every assay was performed in triplicate and 1000 ng cDNA was added to each reaction. 
The specificity of PCR amplification of each primer pair was confirmed by analyzing PCR 
products by agarose gel electrophoresis prior to qRT-PCR. Reference, control and target genes 
were amplified from each cDNA sample using the CFX96 touch real-time PCR detection system 
and SSO advanced universal SYBR green supermix/PowerUpTM SYBRTM Green Master Mix 
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(BIORAD and Thermo Fisher). The cycling condition were according the manufacturer’s 
guidelines. An ABI Prism 7500 Sequence Detector (Applied Biosystems, Hercules, CA) was 
programmed for an initial step of 2 minutes at 50 ◦C and 10 minutes at 95◦C, followed by 40 
thermal cycles of 15 second at 95 ◦C and 1 minute at 60 ◦C. The formula used for fold difference 
calculation was 2-ΔΔCt, where the value of ΔΔCt was the difference in Ct values obtained with 
control and test samples [121]. 
3.4.6 Data analysis 
The Worminator output is written to two comma separated value (CSV) files; one contains 
the average motion detected in the individual well for the analyzed period for each well or plate 
tested, and a second file contains the underlying raw values used in determining the 
aforementioned averages. The average motility scores for the four technical replicates of each 
drug concentration were used in the analysis. The average motility for the control wells was 
calculated by averaging the average motility results of the four negative control wells on each 
plate. The results for the drug containing wells were analyzed in terms of percent inhibition of 
motility at each concentration as compared to the control wells, with a higher percentage motility 
unit inhibition interpreted as a higher level of drug activity (effectiveness). Percentage motility 
inhibition was calculated using a formula average control motility unit minus average treated 
motility units divided by average control motility unit times by one hundred. 
%Motility inhibition =
Average control motility units−Average treated motility units
Average control motility units
 X 100 
Dose response analysis was performed with Graph Pad Prism version 5 using a variable 
slope nonlinear regression model (Graph Pad Software, La Jolla, California, 
USA, http://www.graphpad.com). Drug concentrations were log10 transformed prior to analysis. 
The “log (inhibitor) vs response (four parameters) logistic equation” output provided IC50 values, 
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as well as dose response curves for each drug and time point tested. To determine the motility 
differences between treated and untreated worms, two-way ANOVA and Bonferroni post hoc 
tests were performed. Whereas for relative expressions of different phenotype, one-way ANOVA 
and Bonferroni post hoc tests were used to investigate, if there were significant differences 
between groups treated relative to control and a reference gene Gapdh. 
3.5 Results 
3.5.1 Expression of nAChR subunit genes at the whole worm level  
Preliminary studies were performed to assess the expression level of the nAChR subunits 
at the whole worm level using PCR. The quality of RNA preparations and cDNA synthesis were 
assessed by PCR amplification. The expected ∼200 bp products were amplified with female and 
male cDNA templates (Table 3.1). We designed specific primer and were able to detect 
amplicons. After Worminator assays were done, worms were frozen at -80oC. RNA extractions 
and synthesis of cDNA were performed to check the presence of nAChR genes in the whole 
worms such as Bma-acr-8, Bma-unc-63, Bma-unc-38, Bma-unc-29, Bma-acr-26 and Bma-acr-
16, along with the internal control (Gapdh) (Figure 3-1). After we confirmed the presence of the 
listed genes in the whole worm, qRT-PCR was run to quantify the expression of nAChR subunits. 
Evidently, there are additional subunits present indicating the presence of additional nAChR 
subtypes. Our objective was to investigate the relative expression of the subunits that constitute 











Figure 3-1 A representative gel picture of whole worm PCR reveals the presence of different 
nAChR amplicon expression. Presence of mRNA for Bma-acr-16, Bma-acr-26 Bma-unc-29, 
Bma-unc-38, Bma-unc-63 and Bma-acr-8. gapdh was the internal control for each worm (n = 4, 
all positive for each gene). 
3.5.2 Levamisole transiently inhibits B. malayi motility 
Parasite movement is an important indication of the effectiveness of a drug [20][21]22]. 
We used in vitro B. malayi as a model for assessing the phenotypic changes in motility with 
time course after levamisole administration. Pretreatment worms were healthy and motile, and 
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their average motility was around 30 mmu. Figure 3-3 shows the effect of levamisole was 
quick, potent and levamisole incubation immobilizes the worms very quickly. Male and female 
worms undergo spastic paralysis at low and high concentration of levamisole. But gradually 
worms recovered from spastic paralysis and then progress to flaccid paralysis over 40 minutes. 
We observed a very significant difference between treated and untreated worms during the first 
hour. Then, the next 3 hours, worms recovered gradually and around 4 hours completely 
recovered and their movements was similar to untreated worms. 
  
Figure 3-2  In vitro effects of levamisole on the motility of adult female B. malayi a dose 
response curve observed at the 3 minute time point following. Dose response curve was 
generated applying the variable slope nonlinear regression model analysis contained in 
GraphPad Prism 6. IC50 of 10 nM which indicated worms immediately paralyzed by lower 




The dose response curve reveals that motility was inhibited by 50% at around 10 nM, 
indicating levamisole was initially very potent (Figure 3-2). However, the effects quickly waned 
with time and the worms completely recovered around 4 hours. Possibly, levamisole causes the 
nAChRs at the neuromuscular junction to be downregulated or otherwise desensitized [58]. 
Studies have also revealed that endocytosis of neuromuscular receptors induced by agonist after 
5 minutes of drug applications [122]. But, if this was the cause of the effects of desensitization, 
we need to reason that the relative expression of nAChR subunits would always less than one. 
However, in completely desensitized worms, we measured relative expression of some subunits 
were higher than one. We also need to reason that worms treated with 100 µM levamisole that 







Figure 3-3 In vitro effects of levamisole on the motility of B. malayi following exposure to 
various concentrations of levamisole. Visual examination and Worminator assay indicated, the 
first 10 min all worms were paralyzed which called spastic paralysis; then progresses to flaccid 
paralysis; and then gradually recovery to normal motility. (two-way ANOVA with Bonferroni 
post-hoc test, ***P < 0.001, **P < 0.01, *P < 0.05, n = 4 for each concentration). Statistical 
comparison of between control and 10 µM incubated worms. 
3.5.3 Significant up regulation of Bma-unc-38 increases recovery and motility 
We did phenotypic observation of different concentrations of levamisole to determine 
which concentration to use in subsequent experiments. Recovery of worms was quick at higher 
concentrations of levamisole. We decided to quantify all gene expression changes of nAChRs 
incubated at 100 µM levamisole. We use Worminator video tracking system to measure motility 
of worms quantitatively for 30 sec at different intervals of time for 4 hours. (Figure 3.3) MMU 
(mean motility unity) of female worms at different time courses. In the first 20 minutes, the 
movement of worms exposed to levamisole significantly dropped and come under spastic 
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paralysis. Worms stayed under spastic paralysis; then followed by flaccid paralysis and then 
recovery to normal motility around 4 hours. In the first hour, there was a significant difference 
between treated and control worms. However, at 4 hours worms were completely desensitized 
and no significant difference among treated and untreated worms. This indicates that initially 
levamisole was potent, but with time the effect of the drug was significantly reduced and 
eventually inefficient. We assessed the nAChR subtypes to quantify gene expression changes 
and we compared relative gene expression of treated to untreated worms in the presence of 
internal control. 
 
Figure 3-4 Time-course of the motility of adult female B. malayi following exposure to 100 µM 
of levamisole. Initially treated worms come under spastic paralysis and then desensitized 
quickly to significantly recover at 4 h. (two-way ANOVA with Bonferroni post-hoc test, ***P < 
0.001, **P < 0.01, *P < 0.05, n = 24).      
In completely desensitized female worms, relative expressions of Bma-unc-38 were 
increased in all experimental results. These observations indicate that Bma-unc-38 upregulation 
has an essential role in motility and quickly rescued the worms from paralysis. 
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Previous studies showed dsRNA Knock down of Bma-unc-38/ Bma-unc-29 produce motility 
inhibition that substantiated the role of  Bma-unc-38 in motility [123]. However, in our 
experimental results, we confirmed significant upregulation of Bma-unc-38 rescued the worms 
from paralysis and enhanced recovery. Increased Bma-unc-29 does not rescue the worms from 
paralysis. 
 
Figure 3-5 Quantitative gene expression of nAChRs in female B. malayi after incubation for 4 h 
with 100 µM levamisole and when they were completely desensitized. Bma-unc-38 is 
significantly up-regulated. This suggests, Bma-unc-38 has an essential role in recovery and 
motility. Robust expression of Bma-acr-8 and Bma-unc-63 may also contribute in 
desensitization. (one-way ANOVA with Bonferroni post-hoc test, ***P < 0.001, **P < 0.01, *P 




3.5.4 Worms under flaccid paralysis show significant upregulation of Bma-unc-29   
Around one-hour worms changed their phenotype from spastic paralysis to flaccid 
paralysis. At this stage, the worms remained in paralysis, but relaxed.  The average 
motility of each worms during flaccid phase was less than five MMUs and significantly 
different from untreated worms (Figure 3-6) 
 
Figure 3-6 Motility of adult female B. malayi versus time in the presence and absence of 100 
µM levamisole. In 10 min worms come under spastic paralysis which showed significant 
differences between untreated and treated worms. After 10 min worms gradually escape from 
spastic paralysis to flaccid paralysis and then stayed in flaccid stages for around 40 min (see 
blue line). (two-way ANOVA with Bonferroni post-hoc test, ***P < 0.001, **P < 0.01, *P < 
0.05, n = 12). 
We investigated changes in relative expression of nAChRs and compared to recovered 
worms. Worms under flaccid paralysis shows significant upregulations of Bma-unc-29 (Figure 
3.7). This indicates upregulations of Bma-unc-29 alone do not rescue worms from paralysis but 
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rescued from spastic paralysis. Therefore, this suggests that, complete recovery and motility of 
worms exclusively rely on Bma-unc-38 upregulation. Furthermore, Bma-unc-29 subunit is β - 
subunit and does not form nAChR receptors by itself, it may need an α-subunit to enhance 
desensitization.  
 
Figure 3-7 B. malayi incubated in 100 µM levamisole for 1 h, showed significant upregulation 
of Bma-unc-29. Gene expression of the different subunits of the L-, P-, M- and N- nAChRs 
showing upregulations Bma-unc-29. This suggest that upregulation of Bma-unc-29 alone do not 
rescue the worms from paralysis. (one-way ANOVA with Bonferroni post-hoc test, ***P < 
0.001, **P < 0.01, *P < 0.05, n = 6 with 6 technical replicates).  
 
3.5.5  Desensitization and relative expresssion in male B.malayi 
We have investigated levamisole effects on motitliy in male worms. We ran the same 
experiments as we did in female worms. Worms were exposed to 100 µM of levamisole and 
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motiltiy was measured for 4 hours and relative expressions were assesed. Intially, Motitliy were 
similar to female worms and levamisole was very effective in male as in female worms. The 
first 20 minutes worms came under spastic paralysis followed by flaccid paralysis next 40 
minutes (Figure 3.8). However, varation in motiltiy was observed at 4 hours, male worms did 
not compeletely recover. Motility of control and treated were significantly different at 4 hours. 
In all observations, male worms did not recoved completely, in contrast female worms 
recovered completely at 4 hours. This indicates, levamisole is more effective in male worms 
than female and dthe egree of  desensitzation in females was higher  than  male worms. 
 
Figure 3-8 Motility of adult B. malayi male versus time in the presence and absence of 100 µM 
levamisole. The mean motility of the male worms shows that initially worms come under 
spastic paralysis and then progresses to flaccid paralysis; and then partially recovered at 4 
hours. The degree of desensitization was not as robust as in female worms, we observed 
significant difference between control and treated worms. However, worms were motile. (two-




To investigate the degree of desensitization,we measured the relative expression change 
of male worms and we have observed significant upregulation of Bma-unc-38. This suggests 
that desenstization quickly happens in the presence of robust expression of Bma-acr-8. 
 
 
Figure 3-9 Quantitative gene expression of nAChRs in male B. malayi after incubated for 4 h in 
100 µM levamisole and partially recovered. Bma-unc-38 is significantly up-regulated suggests 
that an important role in recovery and motility. However, robust expression of Bma-unc-29 
together with Bma-unc-38 may form a functional heteromeric receptors which responded to 
levamisole that may delay recovery (one-way ANOVA with Bonferroni post-hoc test, ***P < 






Figure 3-10 Motility of adult male B. malayi versus time in the presence of 100 µM levamisole. 
Initially worms come under spastic paralysis which was significantly different from untreated 
worms. After 10 minutes worms gradually escape from spastic to flaccid paralysis and then stayed 
in flaccid for around 1 h. (see blue line). ( two-way ANOVA with Bonferroni post-hoc test  ***P 




Figure 3-11 Expression of the different nAChR subunits after 1 h incubation in 100 µM 
levamisole. However, no statistical significance (one-way ANOVA with Bonferroni post-hoc test, 
***P < 0.001, **P < 0.01, *P < 0.05, n = 9 with each three technical replicates).  
3.6 Discussion 
We have successfully described the effects of levamisole in male and female adult B. 
malayi using Worminator and qRT-PCR in vitro. The time course of motility and recovery were 
measured at different concentrations of levamisole. Different phenotype changes were measured 
and  charactrerized and we proceeded to measure nAChR subunit gene expressions changes 
during post levamisole adminstration and compared to control worms. Investigation of 
desensitization to anthelmintics using adult B. malayi is the best model, and tractable to study 
motility and molecular pharmacology of their nAChRs. Essential part was to measure the 
motility of the worms at different time and charaterize the phenotypic changes to analyze the 
relative expression changes. 
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3.6.1 Interpretation of the Worminator assay 
In vitro assays are the most efficient and cost-effective means of diagnosing and 
characterizing anthelmintic resistance in nematode populations. The Worminator system is a 
new computer analysis application , with a HD video that measures levamisole effects and 
provide informative dose response data. We have described motility of the female and male 
worms with time course during levamisole incubation. First, we have succesfully characterized 
the phenotypic change of worms during incubation at different levamisole concentrations. 
It has been reported that motility of the adult B. malayi in the presence of levamisole 
dropped by 85 % in 5 and in 10 min, the worms were completely paralyzed. The motility of the 
worms however returned to near control values after 60 min in the drug [82]. Our study 
confirm, we are able to measure motility inhibtion during worms incubated at various 
concentrations ranging from 3 nM to 100 µM. At 10 nM levamisole inhibited motility by 50 % 
in 10 min, but the worms showed motility after one hour. Moreover, visual examination of the 
video showed that during the first minutes all worms immediately come under spastic paralysis 
at both low and high drug concentrations, then followed to flaccid and finally to recovery and 
their  motility were  similar to control worms around 4 hours. This suggests that levamisole is 
intially very potent and causes spastic paralysis, however the effect of levamisole significantly 
reduced with time. 
 Prior study reveals that levamisole acts directly on body wall muscle [124], and they 
provide new molecular evidence for localization of binding sites for levamisole, which opens L-
AChR ion channels in nematode muscle leading to depolarization, spastic muscle contraction, 
and paralysis [125],[126]. We have also observed phenotypic changes of the worms after 
incubation in levamisole that indicates one possible site of levamisole in B.malayi is 
neuromuscular junction. We have investigated the difference in phenotypic changes with time 
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courses in male and female. Our observation reveals that male worms are more susceptible than 
female worms to levamisole. The sensitivity differences of male and female to levamisole are 
complex to comprehend. This suggests nAChR expression varies in male and female after 
exposure to levamisole. Additional study is needed to assess gender based variation sensitivites 
that lead to gender based varation in desensitization.  
Anthelmintic resistance may arise through a number of factors. The possibilites include 
desensitization or downregulation of nAChRs at the neuromuscular junction [58]. Agonist-
induced endocytosis of receptors has been observed in mammalian tissue [122]. We have 
measured gene expression to quantify the nAChR subtype changes. Expresssion changes 
showed differences between male and female worms in most phenotype changes, this 
highlighted that expression pattern of other subunits may have a role in the desensitization. 
Prevous study has reported that Bma-acr-26 was expressed in male muscle but not in female 
muscle [127]. However, our study showed expresssion of  Bma-acr-26 in both male and female 
and the only variation was expression patterns. In all our observations, Bma-acr-26 expression 
level was higher in male than female. This suggests that Bma-acr-26 may also form another 
subtype receptor  that binds to levamisole and delays recovery of the male worms. A study done 
in A. suum reaveals that ACR-26 shared key amino acid residues with loops that form the 
agonist binding sites with α-7 subunits, this suggested that ACR-26 might form homomeric 
nAChRs [128]. 
3.6.2 Gender based variation in desensitization 
The Worminator assay and qRT-PCR results showed that variation in degree of 
desensitization between male and female worms during incubation in levamisole. Using 
Worminator, female worms recovered quickly around 4 hours and their motility were equivalent 
to naive worms. In contrast, male worms did not completely recover at the same hour female 
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recovered. The gender biased difference in motility and desensitization could possibly be due to 
varation in relative expressions pattern of nAChRs, however senstivity to levamisole was 
similar in the first hour. We have observed difference in gene expression of subunits in male 
and female worms. In recovered female and male worms, Bma-unc-38 significantly upregulated 
and possibly accelerate the recovery of motility. This suggests desenstization of worms is 
mainly controlled  by Bma-unc-38. To confirm the role of Bma-unc-38 in B. malayi we needed 
to run knock down of Bma-unc-38. Study has reported, worms exposed to Bma-unc-29 / Bma-
unc-38 dsRNA significantly reduced their motitliy. These observations suggest that UNC-29 
and/or UNC38 are essential for maintaining the motility phenotype. Moreover, sensitivity of 
levamisole also decreases after Bma-unc-29 and Bma-unc-38 knock down [123]. However, 
expression pattern of other subunits were different. These varations in relative expression of 
other subunits could be a reason for varation in degree of desensitization. A study in H. 
contortus has reported Hco-acr-8 is a key determinant of levamisole sensitivity for parasitic 
nematodes [64]. Our study shows that Bma-acr-8 expression of female was higher than male. 
This indicates that Bma-acr-8 may have an important role in recovery of female worms, and 
play a pivotal role in vitro and in vivo in the composition and pharmacological properties of L-
AChRs from other parasitic nematodes. The potential modulation of levamisole sensitivity 
associated with Hco-acr-8 gene silencing was investigated in H. contortus L2 larvae using 
levamisole concentrations corresponding to the minimal efficient doses leading to reduction in 
motility. Strikingly, for both levamisole concentrations, Hco-acr-8 silenced larvae showed a 
reduction of levamisole sensitivity in comparison with the control larvae not subjected to 
silencing. This provides the first in vivo evidence for a key role of ACR-8 in the levamisole 
sensitivity of a parasitic nematode. Besides, robust Bma-acr-8 expression in female, the study 
50 
 
showed expression of Bma-acr-26 in male worms only [129]. However, our study recorded 
expresssion of Bma-acr-26 in male and female worms. The only variation was expression 
patterns in male worm were very robust which substantiate previous study performed in B. 
malayi [129]. In all our experiment, expression levels of male Bma-acr-26 were higher than 
female expression levels. 
In most experiments, worms recovered around 4 hours, and recovery was strongly 
associated to Bma-unc-38. We have investigated relative expressions of Bma-acr-16 and Bma-
acr-26 in male and  female. Though, these are not subunits of nAChR that form the L-type 
receptor. Our study suggests, desensitization abundantly relies on Bma-unc-38 upregulation, but 
varation in desensitization may be also affected by the expression level of other subunits. 
However further study is needed to confirm. Further investigations of Bma-acr-8 by dsRNA 
knock down in female worms may give additional information. In male worms, we observed 
robust upregulations of Bma-acr-26, whereas in female was not. These subunits may not 
directly involve in desensitization, but co-expression with other subunits may form another 
subtype receptor. Study had reported on B. malayi by knocked down acr16+unc-26 and they 
found that there was little effect on motility in contrast to knockdown of Bma-unc-38 / Bma-
unc-29 [123].  
In female worms under flaccid paralysis, we observed a siginificant upregulation of 
Bma-unc-29 that did not rescue the worms from paralysis. This suggests that variation in 
motility and desensitization may be due to upregulation of Bma-unc-38. So far the role of Bma-
unc-38 was studied in female worms but, we need to investigate the role of Bma-unc-29 and 
Bma -acr-8 by dsRNA knock down in male worms as well. 
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Another possible causes of variation of resistance is pharmacokinetic differences in male 
and female. Change in drug metabolism, resulting in inactivation or activation, decrease or 
increase drug elimination; modification in drug distribution, reducing bioavailability to target 
tissues; and/or target gene amplification of the nAChR subunits in order to overcome drug 
action [130]. 
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CHAPTER 4.    CONCLUSION AND FUTURE DIRECTIONS 
4.1 Conclusion 
Many of the currently available anthelmintics used to control parasitic nematode 
infections act on nematode ion channels. However, there are a limited number of these 
anthelmintics, and their repeated use has led to increasing worldwide reports of anthelmintic 
resistance development. Thus, there is an increased need for the development of alternative 
strategies to slow down or overcome the resistance problem. Resistance to anthelmintics is a 
major problem both for human and animal health in combating nematode infections, resulting in 
morbidity and even mortality. The nematode nervous system is a major target site for anthelmintic 
action, including the nAChR. Since there are many nAChR subunits in nematodes not currently 
acting as anthelmintic target sites, these remain potential target sites for new anthelmintics 
The MS research has addressed two strategies by which resistance can be slowed or 
overcome. These include phenotypic characterization of B. malayi to levamisole with time 
courses and molecular analysis of desensitization and flaccid worms. In this study we have 
characterized motility at different times after incubation at different concentrations. Initially, 
levamisole quickly paralyzes the worms no matter the concentration was high or low. However, 
the paralysis was transient which stayed maximum for one hour. In one hour, two phenotype 
changes were observed: spastic paralysis and flaccid paralysis. Then after one hour, worms 
escaped from paralysis and gradual recovery and completely recovered at 4 hours. 
  We compared motility variation and phenotypic changes between male and female adult 
B. malayi. The study has shown, motility of male and female was similar during pretreatment of 
levamisole. However, post treatment both male and female share same phenotypic changes which 
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come under spastic paralysis and then followed by flaccid paralysis. At 4 hours females quickly 
recover to normal motility whereas males showed partial recovery.  
  After we characterize phenotypic changes. We measured the relative expression change 
of the worms to quantify mRNA expression of the subunits using qRT-PCR. Firstly, the 
quantifications were done with female worms. In desensitized female Bma-unc-38 upregulation   
and in worms under flaccid paralysis Bma-unc-29 upregulation were measured respectively. 
Desensitized male worms also showed up regulation of Bma-unc-38. The variation in male and 
female worms were upregulations of other nAChR subunits. During the recovery, in addition to 
Bma-unc-38 upregulation, we found that expression of Bma-acr-8 and Bma-unc-29 were 
increased in female and male respectively. 
  The result suggested that co-expression of Bma-acr-8 with Bma-unc-38 may contribute to 
recovery of the worms from paralysis. In H. controuts, Hco-acr-8 has crucial role. But it needs to 
be investigated further in filaria. The importance of Bma-unc-29 was revealed from worms under 
flaccid paralysis. This subunit did not rescue worms from paralysis. The result was also 
substantiated in male worms, the expression increased but worms were not fully recovered. In 
contrast Bma-unc-29 expression in desensitized female, was not robust, but recovery was fast.  
Finally, our results show that increased expression of Bma-unc-29 and Bma-unc-38 in 
male worms leads to a delay in recovery/desensitization. However, in female worms, we 
measured robust expression of Bma-unc-38 and Bma-acr-8 which worms were quickly recovered 
around one hour. Study has reported in vitro using Xenopus oocytes to determine the expression 
of nAChRs of A. suum. The successfully expressed these genes for the first time in vitro using 
Xenopus oocytes. Expression of Asu-unc-29 and Asu-unc-38 together gave functional heteromeric 
receptors which responded to ACh, levamisole and nicotine but the relative sensitivity to 
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levamisole and nicotine depended on the ratio of the two genes injected into the oocytes. For 
example, when the ratio was 5:1 Asu-unc-38: Asu-unc-29, nicotine was a full agonist but the 
response to levamisole was reduced, an N-type receptor. When the ratio was reversed, levamisole 
became a full agonist while the response to nicotine was reduced, an L-type receptor. When only 
one gene was injected there was no receptor expression. When there are more Bma-unc-29 than 
Bma-unc-38 L-type, then levamisole is effective, and worms delay recovering. Worms under 
flaccid paralysis recorded significant expression of Bma-unc-29 that indicates expression of this 
gene rescues worms from spastic paralysis to flaccid. 
Finally, we have demonstrated the mechanism in which the hypothesis is substantiated 
that the receptors were dynamic otherwise the fold changes of the genes would be the same as 
control. In all phenotypic changes we measured persistent robust expression changes of essential 
genes Bma-unc-29 and Bma-unc-38. Significant expression of Bma-unc-38 has contributed in 
desensitized worms and rescue from paralysis to recovery. However, significant expression Bma-
unc-29 play a role in rescue worms from spastic state to flaccid state. Our study also suggests that 
degree of desensitization was various not due to Bma-unc-38 only however, it could be due to 
other subunits as well.  
We have investigated the gene expression changes of levamisole treated worms in B. 
malayi which was not explored before. Our experiments have provided information on the 
dynamic nature of the nAChR subtypes and how they interact during levamisole attack. We have 
determined the increase expression of levamisole receptor subunits and other subunits. These 
experiments have revealed how worms accommodate to levamisole attack and essential 
information for further study for drug development and discovery.  
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4.2 Future Directions 
We would recommend more experiments be done in order to further confirm the 
function of the Bma-acr-8 and Bma-acr-26 in male and female worms using dsRNA 
Knockdown of both genes. Then using Worminator video tracking system quantify and 
compare motility. 
We would also recommend more experiments be done in order to further information on 
metabolism and bioavailability of the drugs to the worms directly and indirectly way. 
Additional information is need on the fate of drug after worms incubated to the levamisole. 
Using HPLC, we can measure the amount of levamisole at different time and get more 
information on the metabolites directly. Indirectly we can get additional information by 
measuring the amount of the available drugs after 4 h using fresh worm incubation in the same 
well that previously worm incubated. If the new worm incubated in the same well showed the 
same phenotypic changes that may indicates that the amount of unmetabolized drug is high. 
However, if worm does not change the phenotype that indicates metabolism of the drugs may 
contribute in desensitization and recovery. 
 
 
 
 
 
 
 
